Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer

Figure 6

Effects of combination of bezafibrate and GSK126 on protein expressions in bearing tumors of CDXs. (a) Representative bands of western blot of H3K27me3, p-β-catenin, β-catenin, and cleaved caspase 3 in bearing tumors of PANC-1 CDX. (b) Representative bands of western blot of H3K27me3, p-β-catenin, β-catenin, and cleaved caspase 3 in bearing tumors of AsPC-1 CDX. (c) The relative band intensity of H3K27me3 in each experimental group of PANC-1 CDX. (d) The relative band intensity of p-β-catenin in each experimental group of PANC-1 CDX. (e) The relative band intensity of β-catenin in each experimental group of PANC-1 CDX. (f) The relative band intensity of cleaved caspase 3 in each experimental group of PANC-1 CDX. (g) The relative band intensity of cyclin D1 in each experimental group of PANC-1 CDX. (h) The relative band intensity of c-Myc in each experimental group of PANC-1 CDX. (i) The relative band intensity of H3K27me3 in each experimental group of AsPC-1 CDX. (j) The relative band intensity of p-β-catenin in each experimental group of AsPC-1 CDX. (k) The relative band intensity of β-catenin in each experimental group of AsPC-1 CDX. (l) The relative band intensity of cleaved caspase 3 in each experimental group of AsPC-1 CDX. (m) The relative band intensity of cyclin D1 in each experimental group of AsPC-1 CDX. (n) The relative band intensity of c-Myc in each experimental group of AsPC-1 CDX. The values were expressed as the ( for each group). vs. the control group, ^# vs. the Bez group, and ^& vs. the GSK126 group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)